Hypersensitivity pneumonitis: the current state of the problem

Hypersensitive pneumonitis (HP) is an inflammatory interstitial lung disease (ILD) that occurs in predisposed individuals in response to repeated exposure to various aerosol antigens. In 2020 and 2021, specialists made changes to the latest clinical recommendations, to the classification of HP, allowing to distinguish between fibrous and non-fibrous types of HP. The fibrous type is associated with the progression of the disease and an unfavorable prognosis. The diagnosis of HP and its division into types are based on a combination of clinical and anamnestic data, a high-resolution computed tomography (HRCT) picture, the results of cytological examination of bronchoalveolar lavage (BAL) and lung biopsy. Specialists also use lung function tests to determine the progression of the disease. The key diagnostic method is high-resolution computed tomography, which reveals signs of lung tissue pathology («frosted glass», mosaic density) and signs of damage to the small respiratory tract (centrilobular foci, air traps). In fibrotic HP, experts have identified signs of fibrosis: traction bronchiectasis, reticular changes, decreased lung volume, and the formation of a «cellular lung» is possible. Non-fibrotic HP is characterized by: lymphocytic cytogram type (more than 30% of the total number of cells), while in fibrotic HP lymphocytosis is less common. Experts often use lung biopsies for differential diagnosis with other diseases. In nonfibrotic HP, scientists evaluate the signs of involvement of bronchioles and adjacent alveoli in the inflammatory process, the nature of inflammatory infiltration and the presence of granulomas. Fibrotic HP has bronchiolocentric fibrosis, chronic interstitial pneumonia, peribronchiolar metaplasia and other signs. HP therapy includes the elimination of contact with the antigen, the administration of glucocorticosteroids and/or immunosuppressants, as well as antifibrotic therapy in the presence of a progressive variant of fibrous HP.

Contribution:
Suvorova O.A. — research concept and design, data collection and processing, writing the text, editing;
Trushenko N.V. — research concept and design, data collection and processing, writing the text, editing;
Samsonova M.V. — writing the text;
Chernyaev A.L. — writing the text;
Gordeeva A.A. — data collection and processing, writing the text;
Panina U.V. — data collection and processing, writing the text;
Babayan F.Z. — data collection and processing, writing the text;
Avdeev S.N. — research concept and design, editing.

Funding. The study had no funding.

Conflict of interests. The authors declare no conflict of interests.

Received: 06.02.2024 / Accepted: 09.06.2024 / Published: 31.07.2024

1. Raghu G., Remy-Jardin M., Ryerson C.J., Myers J.L., Kreuter M., Vasakova M. et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020; 202: 36–69. https://doi.org/10.1164/rccm.202005-2032ST

2. Fernández Pérez E.R., Travis W.D., Lynch D.A., Brown K.K., Johannson K.A., Selman M. et al. Executive summary diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest. 2021; 160: 595–615. https://doi.org/10.1016/j.chest.2021.03.067

3. Thomeer M.J., Costabel U., Rizzato G., Poletti V., Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur. Respir. J. 2001: 114–118. https://doi.org/10.1183/09031936.01.18s320114

4. Rittig A.H., Hilberg O., Ibsen R, Løkke A. Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study. ERJ Open Res. 2019; 21(54): 00259–2018. https://doi.org/10.1183/23120541.00259-2018

5. Solaymani-Dodaran M., West J., Smith C., Hubbard R. Extrinsic allergic alveolitis: incidence and mortality in the general population. QJM. 2007; 100: 233–237. https://doi.org/10.1093/qjmed/hcm008

6. Fernández Pérez E.R., Kong A.M., Raimundo K., Koelsch T.L., Kulkarni R., Cole A.L. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann. Am. Thorac. Soc. 2018; 15: 460–469. https://doi.org/10.1513/annalsats.201704-288oc

7. Morell F., Villar A., Ojanguren I., Muñoz X., Cruz M.J., Sansano I., et al. Hypersensitivity pneumonitis and (Idiopathic) pulmonary fibrosis due to feather duvets and pillows. Arch. Bronconeumol. 2021; 57: 87–93. https://doi.org/10.1016/j.arbres.2019.12.003

8. Ojanguren I., Morell F., Ramón M.A., Villar A., Romero C., Cruz M.J. et al. Long-term outcomes in chronic hypersensitivity pneumonitis. Allergy. 2019; 74: 944–952. https://doi.org/10.1111/all.13692

9. Fernández Pérez E.R., Sprunger D.B., Ratanawatkul P., Maier L.A., Huie T.J., Swigris J.J. et al. Increasing hypersensitivity pneumonitis–related mortality in the United States from 1988 to 2016. Am. J. Respir. Crit. Care Med. 2019; 199: 1284–1287. https://doi.org/10.1164/rccm.201807-1258le

10. Vasakova M., Morell F., Walsh S., Leslie K., Raghu G. Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2017; 196(6): 680–689. https://doi.org/10.1164/rccm.201611-2201PP PMID: 28598197.

11. Barnes H., Lu J., Glaspole I., Collard H.R., Johannson K.A. Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review. Respir. Med. 2021; 184: 106444. https://doi.org/10.1016/j.rmed.2021.106444

12. Avdeev S.N., Aysanov Z.R., Vizel A.A., Demko I.V., Kinyaikin M.F., Leschenko I.V. et al. Federal clinical guidelines: Hypersensitivity pneumonitis. 2022. https://clck.ru/3BfzBY (in Russian).

13. Johannson K.A., Elicker B.M., Vittinghoff E., Assayag D., de Boer K., Golden J.A. et al. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016; 71(10): 951–954. https://doi.org/10.1136/thoraxjnl-2016-208286

14. Fernández Pérez E.R., Swigris J.J., Forssén A.V., Tourin O., Solomon J.J., Huie T.J. et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013; 144(5): 1644–1651. https://doi.org/10.1378/chest.12-2685

15. Prieto Fernandez A., Palomo Antequera B., Del Castillo Arango K., Blanco Guindel M., Nava Tomas M.E., Mesa Alvarez A.M. Inhalational lung diseases. Radiologia. 2022; 64(3): 290–300. https://doi.org/10.1016/j.rxeng.2022.10.007

16. Selman M., Pardo A., King T. E. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. American journal of respiratory and critical care medicine. 2012; 186: 314–324. https://doi.org/10.1164/rccm.201203-0513CI

17. Ohtsuka Y., Munakata M., Tanimura K., Ukita H., Kusaka H., Masaki Y. et al. Smoking promotes insidious and chronic farmer's lung disease, and deteriorates the clinical outcome. Internal medicine (Tokyo, Japan). 1995; 34, 966–971. https://doi.org/10.2169/internalmedicine.34.966

18. Akkale T., Sarı G., Şimşek C. Occupational hypersensitivity pneumonia. Tuberk Toraks. 2023; 71: 94–104. https://doi.org/10.5578/tt.20239911

19. Vasakova M., Selman M., Morell F., Sterclova M., Molina-Molina M., Raghu G. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am. J. Respir. Crit. Care Med. 2019; 200: 301–308. https://doi.org/10.1164/rccm.201903-0541pp

20. Rijavec M., Volarevic S., Osolnik K., Kosnik M., Korosec P. Natural killer T-cells in pulmonary disorders. Respir. Med. 2011; 105: 20–25. https://doi.org/10.1016/s0954-6111(11)70006-3

21. Lacasse Y., Cormier Y. Hypersensitivity pneumonitis. Orphanet J. Rare Dis. 2006; 1: 25. https://doi.org/10.1186/1750-1172-1-25

22. Barrera L., Mendoza F., Zuñiga J., Estrada A., Zamora A.C., Melendro E.I. et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2008 1; 177: 44–55. https://doi.org/10.1164/rccm.200701-093oc

23. García de Alba C., Buendia-Roldán I., Salgado A., Becerril C., Ramírez R., González Y. et al. Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J. Respir. Crit. Care Med. 2015; 191: 427–436. https://doi.org/10.1164/rccm.201407-1334oc

24. Cottin V., Hirani N.A., Hotchkin D.L., Nambiar A.M., Ogura T., Otaola M. et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018; 27: 180076. https://doi.org/10.1183/16000617.0076-2018

25. Soumagne T., Dalphin J. C. Current and emerging techniques for the diagnosis of hypersensitivity pneumonitis. Expert review of respiratory medicine. 2018; 12(6): 493–507. https://doi.org/10.1080/17476348.2018.1473036

26. Lacasse Y., Selman M., Costabel U., Dalphin J.C., Ando M., Morell F. et al. Clinical diagnosis of hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2003; 168(8): 952–958. https://doi.org/10.1164/rccm.200301-137oc

27. Costabel U., Bonella F., Guzman J. Chronic hypersensitivity pneumonitis. Clin. Chest Med. 2012; 33(1): 151–163. https://doi.org/10.1016/j.ccm.2011.12.004

28. Bourke S.J., Dalphin J.C., Boyd G., McSharry C., Baldwin C.I., Calvert J.E. (2001). Hypersensitivity pneumonitis: current concepts. The European respiratory journal. Supplement. 2001; 32, 81–92. https://doi.org/10.1016/j.ccm.2011.12.004

29. Cormier Y., Lеtourneau L., Racine G. Significance of precipitins and asymptomatic lymphocytic alveolitis: a 20-yr follow-up. Eur. Respir. J. 2004; 23: 523–525. https://doi.org/10.1183/09031936.04.00021104

30. Vandenplas O., Suojalehto H., Aasen T.B., Baur X., Burge P.S., de Blay F. et al.; ERS Task Force on Specific Inhalation Challenges with Occupational Agents. Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement. Eur Respir J. 2014; 43(6): 1573–1587. https://doi.org/10.1183/09031936.00180313

31. Munoz X., Morell F., Cruz M.J. The use of specific inhalation challenge in hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol. 2013; 13: 151–158. https://doi.org/10.1097/aci.0b013e32835e033b

32. Trushenko N.V., Suvorova O.A., Pershina E.S., Nekludova G.V., Chikina S.Y., Levina I.A. et al. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases. Life. 2023; 13: 467. https://doi.org/10.3390/ life13020467

33. Raghu G., Remy-Jardin M., Richeldi L., Thomson C.C., Inoue Y., Johkoh T. et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022; 205: 18–47. https://doi.org/10.1164/rccm.202202-0399st

34. Meyer K.C., Raghu G., Baughman R.P., Brown K.K., Costabel U., du Bois R.M. et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit.l Care Med. 2012; 185(9): 1004–1014. https://doi.org/10.1164/rccm.201202-0320st

35. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am. Rev. Respir. Dis. 1990; 141: 169–202. https://doi.org/10.1164/ajrccm/141.5pt2.s169

36. Santos V., Martins N., Sousa C., Jacob M., Padrao E., Melo N. et al. Hypersensitivity pneumonitis: main features characterization in a Portuguese cohort. Pulmonology. 2019; 29: 130–137. https://doi.org/10.1016/j.pulmoe.2019.09.004

37. Patolia S., Tamae Kakazu M., Chami H.A., Chua A., Diaz-Mendoza J., Duggal A. et al. Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Ann Am Thorac Soc. 2020; (1): 1455–1467. https://doi.org/10.1513/annalsats.202005-420oc

38. Wang L.J., Cai H.R., Xiao Y.L., Wang Y., Cao M.S. Clinical characteristics and outcomes of hypersensitivity pneumonitis: a population-based study in China. Chin. Med. J. 2019; 132(11): 1283–1292. https://doi.org/10.1097/cm9.0000000000000256

39. Tateishi T., Ohtani Y., Takemura T., Akashi T., Miyazaki Y., Inase N. et al. Serial high-resolution computed tomography findings of acute and chronic hypersensitivity pneumonitis induced by avian antigen. J. Comput. Assist. Tomogr. 2011; 35: 272–279. https://doi.org/10.1097/rct.0b013e318209c5a6

40. Barnett J., Molyneaux P.L., Rawal B., Abdullah R., Hare S.S., Vancheeswaran R. et al. Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir J. 2019 25; 54: 1900531. https://doi.org/10.1183/13993003.00531-2019

41. Silva C.I., Churg A., Müller N.L. Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am. J. Roentgenol. 2007; 188: 334–344. https://doi.org/10.2214/ajr.05.1826

42. Dias O.M., Baldi B.G., Pennati F., Aliverti A., Chate R.C., Sawamura M.V.Y. et al. Computed tomography in hypersensitivity pneumonitis: main findings, differential diagnosis and pitfalls. Expert. Rev. Respir. Med. 2018; 12: 5–13. https://doi.org/10.1080/17476348.2018.1395282

43. Walsh S.L., Sverzellati N., Devaraj A., Wells A.U., Hansell D.M. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur. Radiol. 2012; 22: 1672–1679. https://doi.org/10.1007/s00330-012-2427-0

44. Avdeev S.N., Tyurin I.E., Samsonova M.V. Hypersensitivity pneumonitis: X-ray morphological atlas. (Series of the Russian Respiratory Society). Publishing company "Atmosphera"; 2022 (in Russian).

45. Churg A., Sin D.D., Everett D., Brown K., Cool C. Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am. J. Surg. Pathol. 2009; 33: 1765–1770. https://doi.org/10.1097/pas.0b013e3181bb2538

46. Sindhwani G., Shirazi N., Sodhi R., Raghuvanshi S., Rawat J. Transbronchial lung biopsy in patients with diffuse parenchymal lung disease without 'idiopathic pulmonary fibrosis pattern' on HRCT scan — Experience from a tertiary care center of North India. Lung India. 2015; 3: 453–456. https://doi.org/10.4103/0970-2113.164148

47. Churg A. Hypersensitivity pneumonitis: new concepts and classifications. Mod. Pathol. 2022; 35: 15–27. https://doi.org/10.1038/s41379-021-00866-y

48. Petnak T., Thongprayoon C., Baqir M., Ryu J.H., Moua T. Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis. Eur. Respir. J. 2022; 6; 60: 2101336. https://doi.org/10.1183/13993003.01336-2021

49. Nishida T., Kawate E., Ishiguro T., Kanauchi T., Shimizu Y., Takayanagi N. Antigen avoidance and outcome of nonfibrotic and fibrotic hypersensitivity pneumonitis. ERJ Open Res. 2021; 7; 8: 00474–2021. https://doi.org/10.1183/23120541.00474-2021

50. Cano-Jiménez E., Rubal D., Pérez de Llano L.A., Mengual N., Castro-Añón O., Méndez L. et al. Farmer’s lung disease: analysis of 75 cases. Med. Clin. 2017; 149: 429–435. https://doi.org/10.1016/j.medcli.2017.03.052

51. De Sadeleer L., Hermans F., De Dycker E., Yserbyt J., Verschakelen J., Verbeken E. et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J. Clin. Med. 2018; 8:14. https://doi.org/10.3390/jcm8010014

52. Ejima M., Okamoto T., Suzuki T., Anzai T., Takahashi K., Miyazaki Y. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis. BMC Pulm. Med. 2021; 19; 21: 243. https://doi.org/10.1186/s12890-021-01608-1

53. Tony F.A., Soliman Y.M.A., Salem H.A. Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis. J. Asthma Allergy. 2021; 10; 14: 501–511. https://doi.org/10.2147/jaa.s299939

54. Lewandowska K.B., Barańska I., Sobiecka M., Radwan-Rohrenschef P., Dybowska M., Franczuk M. et al. Factors Predictive for Immunomodulatory Therapy Response and Survival in Patients with Hypersensitivity Pneumonitis-Retrospective Cohort Analysis. Diagnostics (Basel). 2022; 12: 2767. https://doi.org/10.3390/diagnostics12112767

55. Salisbury M.L., Myers J.L., Belloli E.A., Kazerooni E.A., Martinez F.J., Flaherty K.R. Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. Am. J. Respir. Crit. Care Med. 2017; 196 (15): 690–699. https://doi.org/10.1164/rccm.201608-1675pp

56. De Sadeleer L.J., Hermans F., De Dycker E., Yserbyt J., Verschakelen J.A., Verbeken E.K. et al. Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study. J. Clin. Med. 2018; 21; 8: 14. https://doi.org/10.3390/jcm8010014

57. Fiddler C.A., Simler N., Thillai M., Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis — A single-centre experience. Clin Respir J. 2019; 13(12): 791–794. https://doi.org/10.1111/crj.13086

58. Morisset J., Johannson K.A., Vittinghoff E., Aravena C., Elicker B.M., Jones K.D. et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2017; 151: 619625. https://doi.org/10.1016/j.chest.2016.10.029

59. Wong A.W., Khor Y.H., Donohoe K., Comes A., Marcoux V., Fisher J.H. et al. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Ann. Am. Thorac Soc. 2022; 19: 863–867. https://doi.org/10.1513/annalsats.202108-954rl

60. Noh S., Yadav R., Li M., Wang X., Sahoo D., Culver D.A. et al. Use of leflunomide in patients with chronic hypersensitivity pneumonitis. BMC Pulm Med. 2020; 20(1): 199. https://doi.org/10.1186/s12890-020-01227-2

61. Ferreira M., Borie R., Crestani B., Rigaud P., Wemeau L., Israel-Biet D et al.; of the OrphaLung network. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med. 2020; 172: 106146. https://doi.org/10.1016/j.rmed.2020.106146

62. Keir G.J., Maher T.M., Ming D., Abdullah R., de Lauretis A., Wickremasinghe M. et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014; 19: 353–9. https://doi.org/10.1111/resp.12214

63. Ceci Bonello E., Gauci J., Bonello S., Fsadni P., Montefort S. Rituximab therapy in a patient with steroid-refractory bird fancier's lung. BMJ Case Rep. 2020; 13: 237232. https://doi.org/10.1136/bcr-2020-237232

64. Flaherty K.R., Wells A.U., Cottin V., Devaraj A., Walsh S.L.F., Inoue Y. et al.; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019; 381: 1718–1727. https://doi.org/10.1056/nejmoa1908681

65. Behr J., Prasse A., Kreuter M., Johow J., Rabe K.F., Bonella F. et al. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2021; 9: 476–486. https://doi.org/10.1016/s2213-2600(20)30554-3

66. Mateos-Toledo H., Mejía-Ávila M., Rodríguez-Barreto Ó., Mejía-Hurtado J.G., Rojas-Serrano J., Estrada A. et al. An Open-label Study with Pirfenidone on Chronic Hypersensitivity Pneumonitis. Arch. Bronconeumol. (Engl. Ed.). 2020; 56: 163–169. https://doi.org/10.1016/j.arbres.2019.08.019

67. Shebl E., Hamdy T. Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis. Egypt J Bronchol. 2021; 15: 18. https://doi.org/10.1186/s43168-021-00065-y

68. Fernández Pérez E.R., Crooks J.L., Lynch D.A., Humphries S.M., Koelsch T.L., Swigris J.J. et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023; 78: 1097–1104. https://doi.org/10.1136/thorax-2022-219795

69. Kern R.M., Singer J.P., Koth L., Mooney J., Golden J., Hays S. et al. Lung transplantation for hypersensitivity pneumonitis. Chest. 2015; 147(6): 1558–1565. https://doi.org/10.1378/chest.14-1543

70. Kozu R., Shingai K., Hanada M., Oikawa M., Nagura H., Ito H. et al. Respiratory Impairment, Limited Activity, and Pulmonary Rehabilitation in Patients with Interstitial Lung Disease. Phys. Ther. Res. 2021; 24: 9–16. https://doi.org/10.1298/ptr.r0012

71. Dowman L., Hill C.J., May A., Holland A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021; 2: CD006322. https://doi.org/10.1002/14651858.cd006322.pub4